ALTAltimmune, Inc.

$353M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5,000+0.0% YoY

Gross Profit

$5,000100.0% margin

Operating Income

-$23M-458440.0% margin

Net Income

-$22M-442920.0% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$190M

Total Liabilities

$29M

Stockholders' Equity

$161M

Cash & Equivalents

$183M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5,000	$5,000	+0.0%
Gross Profit	$5,000	$5,000	+0.0%
Operating Income	-$23M	-$27M	+14.3%
Net Income	-$22M	-$25M	+10.1%

ALT Q2 2025 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena